6 June 2017

Holding(s) in Company

 

For filings with the FCA include the annex

For filings with issuer exclude the annex
 
   
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
   
1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ii
Verona Pharma plc 
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached  
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments  
An event changing the breakdown of voting rights  
Other (please specify):    
3. Full name of person(s) subject to the
notification obligation:
iii
Aisling Capital Management LP

Aisling Capital IV LP
4. Full name of shareholder(s)
 (if different from 3.):iv
Aisling Capital IV LP
5. Date of the transaction and date on
which the threshold is crossed or
reached:
v
05/19/2017
6. Date on which issuer notified: 05/26/2017
7. Threshold(s) that is/are crossed or
reached:
vi, vii
Upward crossing of 3% threshold
 
8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of
shares



if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of shares
Number of voting
rights
% of  voting rights x
Direct Direct xi Indirect xii Direct Indirect
Ordinary

ISIN GB00B06GSH43
 

 

 

 

 

 
 

 

 

 

 

 
 

 

1,474,688

 

 

 

2,074,080
 

 

1,474,688

 

 

 

2,074,080
 

 

 

 

 

 

 
 

 

1.41%

 

 

 

1.98%
 

 

 
 

ADS

ISIN US9250501064
 
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
Expiration
date
xiii
Exercise/
Conversion Period
xiv
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
% of voting
rights
         
 
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial
instrument
Exercise price Expiration date xvii Exercise/
Conversion period
xviii
Number of voting rights instrument refers to

 
% of voting rights xix, xx

 
         

 
Nominal Delta
   
 
Total (A+B+C)
Number of voting rights Percentage of voting rights
3,548,768 3.38%
 
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi
 

Aisling Capital IV LP (which holds 3,548,768 shares in the Company (3.38%)) is managed by Aisling Capital Management LP.

 

 
Proxy Voting:
10. Name of the proxy holder:  
11. Number of voting rights proxy holder will cease
to hold:
 
12. Date on which proxy holder will cease to hold
voting rights:
 
 

13. Additional information:

 
14. Contact name: Robert Wenzel
15. Contact telephone number: 212-651-6374
 
Note: Annex should only be submitted to the FCA not the issuer

Annex: Notification of major interests in share (xxii)
 
A: Identity of the persons or legal entity subject to the notification obligation
Full name

(including legal form of legal entities)
Aisling Capital IV LP
Contact address

(registered office for legal entities)
888 7th Avenue, 12th floor

New York, NY 10106
Phone number & email 212-651-6380 / rwenzel@aislingcapital.com
Other useful information

(at least legal representative for legal persons)
 
   
B: Identity of the notifier, if applicable
Full name

 
 
Contact address

 
 
Phone number & email  
Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)
 
 
C: Additional information
 
For notes on how to complete form TR-1 please see the FCA website.
 
 
 
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Verona Pharma plc via Globenewswire

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us